Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 24, 2014 06:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin and Prosensa Holding N.V. Reach Agreement on Intended Public Offer for 100% of Prosensa's Outstanding Stock; Will Add Duchenne Muscular Dystrophy Products to Rare-Disease Portfolio

Acquisition of Prosensa provides near-term opportunity to commercialize, if approved, its exon-skipping drug candidate,drisapersen, for Duchenne muscular dystrophy (DMD) Drisapersen...
November 19, 2014 08:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin to Attend Upcoming Investor Conferences

Deutsche Bank BioFEST on December 2 Piper Jaffray Healthcare Conference on December 3 SAN RAFAEL, Calif., Nov. 19, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), today...
November 04, 2014 08:00 ET | Source: BioMarin Pharmaceutical Inc.

Jean-Jacques Bienaime, CEO of BioMarin, to Present at the Credit Suisse 2014 Healthcare Conference

SAN RAFAEL, Calif., Nov. 4, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), today announced that Jean-Jacques Bienaimé, Chief Executive Officer at BioMarin, will present at...
October 23, 2014 16:01 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Announces Third Quarter 2014 Financial Results

- VIMIZIM® Sales Top $25 million in Second Full Quarter of Sales - Full Year Total BioMarin Revenue Guidance Increased Financial Highlights ($ in millions, except per share data,...
October 08, 2014 08:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin to Host Third Quarter 2014 Financial Results Conference Call and Webcast on Thursday, October 23 at 4:30pm ET

SAN RAFAEL, Calif., Oct. 8, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaimé, Chief Executive Officer of BioMarin, will host a...
September 24, 2014 17:21 ET | Source: BioMarin Pharmaceutical Inc.

FDA Receives Paragraph IV Notice Letter for KUVAN(R) (sapropterin dihydrochloride) Tablets

SAN RAFAEL, Calif., Sept. 24, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that a Paragraph IV Certification Notice Letter was submitted to the US Food and Drug...
September 23, 2014 08:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin to Attend Upcoming Investor Conferences

- Jefferies Gene Therapy Summit on September 30 in Boston - Leerink Partners Rare Disease Roundtable on October 1 in New York SAN RAFAEL, Calif., Sept. 23, 2014 (GLOBE NEWSWIRE) -- BioMarin...
September 15, 2014 08:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Named by CenterWatch as One of the Fastest Developers of Medicines

SAN RAFAEL, Calif., Sept. 15, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that CenterWatch, a leading source for global clinical trial information, has named it...
September 10, 2014 08:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin to Attend Upcoming Investor Conferences in London

- J.P. Morgan Annual U.S. All Stars Conference in London on September 16 - Bank of America Merrill Lynch Global Healthcare Conference in London on September 17 SAN RAFAEL, Calif., Sept. 10, 2014...
August 19, 2014 08:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin to Present at Upcoming Investor Conferences

- Baird 2014 Healthcare Conference on September 3 - Citi Annual Biotech Conference on September 4 - Morgan Stanley Global Healthcare Conference on September 9 SAN RAFAEL, Calif., Aug. 19,...